36 Healthcare Stocks Moving In Monday's Pre-Market Session

Gainers

• Sorrento Therapeutics, Inc. SRNE stock surged 35.0% to $2.16 during Monday's pre-market session. The market cap seems to be at $215.6 million. The most recent rating by JMP Securities, on October 07, is at Market Outperform, with a price target of $21.00.
• Medicines Co, Inc. MDCO stock increased by 23.1% to $84.40. The market cap stands at $4.1 billion. The most recent rating by Baird, on November 25, is at Neutral, with a price target of $85.00.
• Enochian BioSciences, Inc. ENOB shares surged 19.2% to $7.00. The market cap seems to be at $263.7 million.
• Aquestive Therapeutics, Inc. AQST stock rose 18.2% to $7.60. The market value of their outstanding shares is at $96.1 million.
• AnaptysBio, Inc. ANAB stock surged 15.2% to $13.85. The market cap stands at $1.0 billion. According to the most recent rating by Guggenheim, on November 08, the current rating is at Neutral.
• Alnylam Pharmaceuticals, Inc. ALNY shares surged 7.6% to $115.00. The market value of their outstanding shares is at $9.6 billion. The most recent rating by Barclays, on November 21, is at Overweight, with a price target of $131.00.
• Proteostasis Therapeutics, Inc. PTI shares surged 6.9% to $1.87. The market value of their outstanding shares is at $42.4 million.
• ZIOPHARM Oncology, Inc. ZIOP stock rose 6.8% to $5.04. The market cap seems to be at $763.9 million.
• Intercept Pharmaceuticals, Inc. ICPT stock moved upwards by 6.3% to $94.50. The market cap seems to be at $2.3 billion. The most recent rating by UBS, on November 12, is at Buy, with a price target of $135.00.
• Myovant Sciences, Inc. MYOV shares moved upwards by 6.0% to $14.90. The market cap seems to be at $489.3 million. The most recent rating by Goldman Sachs, on August 28, is at Buy, with a price target of $20.00.
• Arrowhead Pharmaceuticals, Inc. ARWR shares moved upwards by 6.0% to $52.16. The market value of their outstanding shares is at $2.6 billion. The most recent rating by Baird, on November 25, is at Outperform, with a price target of $70.00.
• Clovis Oncology, Inc. CLVS stock increased by 5.3% to $9.12. The market cap stands at $173.7 million. The most recent rating by Evercore ISI Group, on November 19, is at In-Line, with a price target of $8.00.
• Karuna Therapeutics, Inc. KRTX shares moved upwards by 4.7% to $89.00. The market value of their outstanding shares is at $325.9 million. The most recent rating by Goldman Sachs, on November 18, is at Buy, with a price target of $109.00.
• Viveve Medical, Inc. VIVE stock increased by 4.4% to $0.96. The market cap stands at $6.8 million. The most recent rating by Stifel Nicolaus, on November 07, is at Hold, with a price target of $1.00.
• BioCryst Pharmaceuticals, Inc. BCRX shares moved upwards by 4.0% to $2.34. The market cap seems to be at $220.8 million. According to the most recent rating by Bank of America, on November 15, the current rating is at Buy.
• Canopy Growth, Inc. CGC shares increased by 3.8% to $19.10. The market cap seems to be at $6.9 billion. According to the most recent rating by Bank of America, on November 20, the current rating is at Buy.
• Zealand Pharma, Inc. ZEAL stock rose 3.7% to $31.16. The market cap stands at $1.0 billion. According to the most recent rating by Jefferies, on November 19, the current rating is at Hold.
• Organogenesis Holdings, Inc. ORGO shares increased by 3.7% to $4.90. The market cap seems to be at $664.1 million.
• Intra-Cellular Therapies, Inc. ITCI stock rose 3.6% to $10.34. The market cap stands at $511.0 million.
• Mylan, Inc. MYL shares increased by 3.5% to $17.95. The market cap stands at $9.8 billion. The most recent rating by Morgan Stanley, on November 07, is at Equal-Weight, with a price target of $18.00.
• Diffusion Pharmaceuticals, Inc. DFFN shares increased by 3.2% to $0.32. The market value of their outstanding shares is at $3.9 million.
• DelMar Pharmaceuticals, Inc. DMPI stock increased by 2.9% to $1.08. The market cap stands at $7.6 million. The most recent rating by Maxim Group, on September 06, is at Buy, with a price target of $2.00.
• Teva Pharmaceutical Indus, Inc. TEVA stock surged 2.7% to $10.50. The market value of their outstanding shares is at $8.9 billion. According to the most recent rating by JP Morgan, on November 12, the current rating is at Neutral.
• CRISPR Therapeutics, Inc. CRSP stock surged 2.6% to $63.85. The market cap stands at $2.7 billion. The most recent rating by Oppenheimer, on November 12, is at Outperform, with a price target of $65.00.
• Ocugen, Inc. OCGN shares increased by 2.6% to $0.29. The market cap seems to be at $19.7 million.

Losers

• CymaBay Therapeutics, Inc. CBAY stock plummeted 79.6% to $1.13 during Monday's pre-market session. The market cap seems to be at $308.4 million.
• Adamis Pharmaceuticals, Inc. ADMP stock declined 52.4% to $0.60. The market value of their outstanding shares is at $49.7 million.
• ASLAN Pharmaceuticals, Inc. ASLN shares fell 24.3% to $1.31. The market value of their outstanding shares is at $49.3 million. The most recent rating by H.C. Wainwright, on November 14, is at Buy, with a price target of $2.00.
• InVivo Therapeutics Hldg, Inc. NVIV shares fell 12.1% to $0.14. The market cap stands at $4.3 million.
• Phio Pharmaceuticals, Inc. PHIO stock declined 7.8% to $0.12. The market cap seems to be at $5.7 million.
• Guardion Health Sciences, Inc. GHSI shares decreased by 5.7% to $0.20. The market value of their outstanding shares is at $20.3 million.
• OrganiGram Holdings, Inc. OGI shares declined 4.9% to $2.51. The market cap seems to be at $536.7 million.
• OpGen, Inc. OPGN stock plummeted 3.9% to $1.22. The market cap seems to be at $4.5 million.
• Genfit, Inc. GNFT stock plummeted 3.8% to $14.65. The market value of their outstanding shares is at $552.9 million.
• Eyegate Pharmaceuticals, Inc. EYEG stock plummeted 3.7% to $6.83. The market cap stands at $14.3 million.
• VBI Vaccines, Inc. VBIV stock fell 3.2% to $0.62. The market cap seems to be at $104.2 million. The most recent rating by Raymond James, on November 14, is at Outperform, with a price target of $3.00.
• Onconova Therapeutics, Inc. ONTX stock declined 2.9% to $0.15. The market cap stands at $4.3 million.